Navigation Links
New Pill Might Relieve Severe Rheumatoid Arthritis
Date:8/8/2012

By Barbara Bronson Gray
HealthDay Reporter

WEDNESDAY, Aug. 8 (HealthDay News) -- A new oral medication may be available soon for people with rheumatoid arthritis who have not gained relief from other medicines.

As rheumatoid arthritis progresses, people often struggle with everyday tasks and find walking difficult. To help combat those issues, patients with severe forms of the disease often need drugs that must be injected, typically twice a month.

The new drug, tofacitinib, was approved by an advisory panel of the U.S. Food and Drug Administration in May and could be green-lighted by the FDA this month. However, the drug carries the risk of serious side effects, as do injectable treatments. The risks include blood and lymphatic system disorders, infections, and cancer.

"This is an advance, but it's not a cure-all," said Dr. Roy Fleischmann, study author and clinical professor of medicine at the University of Texas Southwestern Medical Center, in Dallas. "We have not cured rheumatoid arthritis."

Rheumatoid arthritis, which differs from age-related osteoarthritis, is a debilitating autoimmune disorder, meaning the body attacks its own tissues. It is characterized by inflammation of the lining, or synovium, of the joints.

The new drug, called a JAK inhibitor, blocks signals that activate inflammatory immune responses involved in the disease.

The FDA is not required to follow its panel's recommendations, but it usually does. Further evidence supporting the benefits of the drug comes in two studies published Aug. 9 in the New England Journal of Medicine.

Fleishmann explained that while people with the disease have benefitted from the discovery of "biologic" drugs such as Humira (adalimumab), Enbrel (etanercept) and Remicade (infliximab), many patients don't find relief from these medications. Biologic products are large proteins that are available only by injection or intravenous administration. The hope, he said, is that JAK inhibitors will help improve the lives of those not getting enough relief from other medications.

Both studies were phase 3 clinical trials, used to test the effectiveness and safety of potential drug therapies in large groups of people.

In Fleischmann's research, about 700 patients who had been taking methotrexate -- a commonly used drug for rheumatoid arthritis -- with inadequate relief were randomly assigned to take either 5 milligrams (mg) or 10 mg of tofacitinib twice daily, 40 mg of Humira every two weeks, or an inactive placebo.

Patients in the placebo group who didn't see notable improvement in their joint pain were switched after three months to get either 5 mg or 10 mg of tofacitinib. Participants were rated on a commonly used index of disability and checked for clinical signs of disease activity. The 12-month study showed that tofacitinib was superior to placebo and similar to Humira in its effectiveness.

The second study involved about 610 patients who had had an inadequate response to methotrexate. Tofacitinib was found to be associated with reductions in symptoms of rheumatoid arthritis and improvement in physical functioning.

Experts not associated with the study think the new drug, if approved by the FDA, would be a positive treatment option.

"It looks like tofacitinib could be used as a first-line agent, before taking a patient to a biologic," said Dr. Ernest Brahn, professor of medicine and rheumatology training program director at University of California, Los Angeles School of Medicine.

However, he noted that the studies involved a relatively small number of patients and no long-term data.

Dr. David Fox, of the rheumatology division at University of Michigan, Ann Arbor, writes in an accompanying journal editorial that a better understanding of the drug's safety picture is needed to determine at what point patients might turn to tofacitinib.

The cost of the drugs, if approved, is unknown. "My guess is that it will be close to the price of the biologics," said Brahn. Fleischmann estimated that the current cost of those drugs to a consumer without insurance is about $25,000 a year.

Tofacitinib would be manufactured by Pfizer Inc., which funded both studies.

Rheumatoid arthritis affects about 1.3 million Americans, according to the Arthritis Foundation.

More information

The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases has more about rheumatoid arthritis.

SOURCES: Roy Fleischmann, M.D., clinical professor, medicine, University of Texas Southwestern Medical Center, Dallas; Ernest Brahn, M.D., professor, medicine, and rheumatology training program director, University of California, Los Angeles School of Medicine; Aug. 9, 2012, New England Journal of Medicine


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Fainting Might Run in Families, Twin Study Finds
2. Why do older adults display more positive emotion? It might have to do with what they’re looking at
3. Living Without Lies Might Make You Healthier
4. Child Abuse Might Alter Onset of Menstruation in Girls
5. Musicians Brains Might Have an Edge on Aging
6. Too Much Bottled Water Might Harm Kids Teeth
7. Smile! It Might Lower Your Stress Level, Study Shows
8. Humans Might Be Hard-Wired to Love Thy Neighbor
9. More Evidence That Shift Work Might Raise Heart Risks
10. Yoga Might Help With Stroke Rehab
11. Certain Tick Bites Might Spur Red Meat Allergy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Pill Might Relieve Severe Rheumatoid Arthritis
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: